Lantern Pharma Inc reports results for the quarter ended in December - Earnings Summary

Lantern Pharma

18/03/2024 21:01

* Lantern Pharma Inc  LTRN.OQ  reported a quarterly adjusted
loss
of 39 cents​​ per share for the quarter ended in December, lower
than the same quarter last year, when the company reported EPS
of -31 cents.  The mean expectation of two analysts for the
quarter was for a loss of 40 cents per share. Wall Street
expected results to range from -48 cents to -32 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Lantern Pharma Inc's reported EPS for the quarter was a
loss
of 39 cents​.
    * The company reported a quarterly loss of $4.19 million.
    * Lantern Pharma Inc shares had risen by 103.3% this
quarter.

FORECAST CHANGES
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 
    * Wall Street's median 12-month price target for Lantern
Pharma
Inc is $20.50 

This summary was machine generated from LSEG data March 18 at
09:00 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2023      -0.40          -0.39          Beat
 Sep. 30 2023      -0.45          -0.29          Beat
 Jun. 30 2023      -0.43          -0.44          Missed
 Mar. 31 2023      -0.48          -0.36          Beat